Cowen & Co. Sticks to Their Hold Rating for PDL BioPharma (PDLI)


Cowen & Co. analyst Phil Nadeau maintained a Hold rating on PDL BioPharma (PDLI) today and set a price target of $3. The company’s shares opened today at $2.46.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.5% and a 50.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Alexion Pharmaceuticals.

PDL BioPharma has an analyst consensus of Hold, with a price target consensus of $3.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.18 and a one-year low of $2.25. Currently, PDL BioPharma has an average volume of 1.27M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts